What is it about?
Peyronie's disease (PD) is a fibrotic disorder of penile tunica albuginea with no effective medical treatments. We have screened 1,953 FDA approved drugs on a cellular model of PD. From this screen we have identified 26 hit drugs which have the potential to be repurposed for PD.
Featured Image
Photo by Louis Reed on Unsplash
Why is it important?
PD presents in two phases: acute phase while fibrosis is still active and the plaque is forming followed by a chronic phase when the plaque stabilises. Eventually PD can cause penile curvature, erectile dysfunction and penile shortening. Currently there are no treatments for the acute phase. In the chronic phase the patient can be offered collagenase injection and/or surgery. In our Fibrosis Research Group we aim to find novel therapeutic approaches that can slow or halt the progression of acute phase PD. 26 hits identified in this study have the potential to be repurposed for this significant unmet need.
Perspectives
We hope that the fellow scientists in the field of PD and maybe those in wider fibrosis field will benefit from this paper and the accompanying data set of the results from 1,953 FDA-approved drugs and this will lead to discovery of novel anti-fibrotics.
Selim Cellek
Anglia Ruskin University
Read the Original
This page is a summary of: Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie’s disease, PLoS ONE, December 2022, PLOS,
DOI: 10.1371/journal.pone.0277646.
You can read the full text:
Resources
Contributors
The following have contributed to this page
